BioNexus Gene Lab Corp SEC filings BGLC
BioNexus Gene Lab Corp has 157 filings in SEC EDGAR's recent list, going back to Jan 29, 2019. Its latest annual report, Form 10-K, was filed on Apr 14, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 14, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 7, 2026 (material agreement, unregistered share sale, regulation fd disclosure). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Material agreement, Unregistered share sale, Regulation FD disclosure
|
Oct 7, 2026 | Oct 5, 2026 |
| 10-Q | Quarterly report | Aug 14, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Other events
|
Jul 28, 2026 | Jul 28, 2026 |
| 8-K |
Current report
Other events
|
Jun 5, 2026 | May 29, 2026 |
| 10-Q | Quarterly report | May 15, 2026 | Mar 31, 2026 |
| 10-K | Annual report | Apr 14, 2026 | Dec 31, 2025 |
| NT 10-K | Filing | Mar 31, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Mar 17, 2026 | Mar 11, 2026 |
| 8-K |
Current report
Other events
|
Feb 23, 2026 | Feb 23, 2026 |
| 8-K |
Current report
Other events
|
Feb 3, 2026 | Jan 28, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Dec 30, 2025 | Dec 24, 2025 |
| 8-K |
Current report
Other events
|
Dec 23, 2025 | Dec 19, 2025 |
| DEF 14A | Proxy statement | Dec 3, 2025 | Dec 24, 2025 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Regulation FD disclosure
|
Dec 2, 2025 | Nov 28, 2025 |
| 10-Q | Quarterly report | Nov 14, 2025 | Sep 30, 2025 |
| PRE 14A | Preliminary proxy statement | Nov 14, 2025 | Nov 14, 2025 |
| 8-K |
Current report
Material agreement, Regulation FD disclosure
|
Nov 13, 2025 | Nov 7, 2025 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Regulation FD disclosure
|
Nov 12, 2025 | Nov 12, 2025 |
| S-3 | Shelf registration | Nov 7, 2025 | — |
| 8-K |
Current report
Regulation FD disclosure
|
Oct 23, 2025 | Oct 20, 2025 |
| 10-Q | Quarterly report | Aug 18, 2025 | Jun 30, 2025 |
| NT 10-Q | Filing | Aug 14, 2025 | Jun 30, 2025 |
| 8-K |
Current report
Regulation FD disclosure
|
Jul 30, 2025 | Jul 30, 2025 |
| 8-K |
Current report
Officer or director change
|
Jun 23, 2025 | Jun 17, 2025 |
| 10-Q | Quarterly report | May 15, 2025 | Mar 31, 2025 |
| 8-K |
Current report
Listing notice, Regulation FD disclosure
|
Apr 30, 2025 | Apr 30, 2025 |
| 10-K/A | Amended annual report | Apr 29, 2025 | Dec 31, 2024 |
| 10-K | Annual report | Apr 15, 2025 | Dec 31, 2024 |
| 8-K |
Current report
Change to shareholder rights
|
Apr 10, 2025 | Apr 7, 2025 |
| 8-K |
Current report
Change to shareholder rights, Bylaw or fiscal year change
|
Apr 3, 2025 | Apr 1, 2025 |
| NT 10-K | Filing | Mar 31, 2025 | Dec 31, 2024 |
| 8-K |
Current report
Shareholder vote results
|
Mar 25, 2025 | Mar 19, 2025 |
| 8-K |
Current report
Regulation FD disclosure
|
Mar 7, 2025 | Mar 7, 2025 |
| 8-K |
Current report
Other events
|
Mar 5, 2025 | Mar 5, 2025 |
| DEFR14A | Defr 14a | Feb 28, 2025 | — |
| DEF 14A | Proxy statement | Feb 27, 2025 | Mar 19, 2025 |
| 8-K |
Current report
Unregistered share sale, Change to shareholder rights, Bylaw or fiscal year change
|
Feb 14, 2025 | Feb 11, 2025 |
| PRE 14A | Preliminary proxy statement | Feb 10, 2025 | Feb 10, 2025 |
| 8-K |
Current report
Listing notice
|
Jan 2, 2025 | Dec 27, 2024 |
| 10-Q | Quarterly report | Nov 15, 2024 | Sep 30, 2024 |
| NT 10-Q | Filing | Nov 14, 2024 | Sep 30, 2024 |
| 8-K |
Current report
Listing notice, Officer or director change
|
Nov 8, 2024 | Nov 5, 2024 |
| 8-K |
Current report
Officer or director change
|
Oct 15, 2024 | Oct 9, 2024 |
| 8-K |
Current report
Shareholder vote results, Other events
|
Oct 10, 2024 | Oct 4, 2024 |
| 8-K |
Current report
Material agreement, Other events
|
Sep 25, 2024 | Sep 23, 2024 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 18, 2024 | Sep 14, 2024 |
| DEF 14A | Proxy statement | Sep 16, 2024 | Oct 4, 2024 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 12, 2024 | Sep 11, 2024 |
| PRE 14A | Preliminary proxy statement | Sep 6, 2024 | Sep 6, 2024 |
| 8-K |
Current report
Bylaw or fiscal year change
|
Sep 5, 2024 | Sep 4, 2024 |
| 8-K |
Current report
Regulation FD disclosure
|
Aug 28, 2024 | Aug 27, 2024 |
| 8-K |
Current report
Material agreement, Regulation FD disclosure, Other events
|
Aug 26, 2024 | Aug 26, 2024 |
| 10-Q | Quarterly report | Aug 14, 2024 | Jun 30, 2024 |
| 8-K/A |
Amended current report
Officer or director change
|
Jul 5, 2024 | Mar 26, 2024 |
| UPLOAD | Letter from the SEC | Jun 6, 2024 | — |
| 10-K/A | Amended annual report | May 31, 2024 | Dec 31, 2023 |
| 10-Q/A | Amended quarterly report | May 31, 2024 | Sep 30, 2023 |
| 10-Q/A | Amended quarterly report | May 31, 2024 | Jun 30, 2023 |
| 10-Q/A | Amended quarterly report | May 31, 2024 | Mar 31, 2023 |
| 10-K/A | Amended annual report | May 31, 2024 | Dec 31, 2022 |
| CORRESP | Letter to the SEC | May 23, 2024 | — |
| 10-Q | Quarterly report | May 15, 2024 | Mar 31, 2024 |
| 8-K |
Current report
Listing notice
|
May 9, 2024 | May 8, 2024 |
| UPLOAD | Letter from the SEC | May 6, 2024 | — |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Apr 18, 2024 | Apr 18, 2024 |
| 10-K | Annual report | Apr 16, 2024 | Dec 31, 2023 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
Apr 1, 2024 | Mar 26, 2024 |
| NT 10-K | Filing | Mar 28, 2024 | Dec 31, 2023 |
| 10-Q/A | Amended quarterly report | Mar 26, 2024 | Sep 30, 2023 |
| DEF 14C | Information statement | Feb 29, 2024 | Feb 29, 2024 |
| PRE 14C | Filing | Jan 26, 2024 | Jan 26, 2024 |
| 10-Q | Quarterly report | Nov 20, 2023 | Sep 30, 2023 |
| NT 10-Q | Filing | Nov 14, 2023 | Sep 30, 2023 |
| 8-K |
Current report
Listing notice
|
Nov 13, 2023 | Nov 6, 2023 |
| 8-K |
Current report
Officer or director change
|
Nov 3, 2023 | Oct 30, 2023 |
| 8-K/A |
Amended current report
Officer or director change
|
Oct 30, 2023 | Oct 12, 2023 |
| 8-K |
Current report
Officer or director change
|
Oct 16, 2023 | Oct 12, 2023 |
| 8-K |
Current report
Officer or director change
|
Oct 11, 2023 | Oct 4, 2023 |
| 8-K |
Current report
Officer or director change
|
Sep 7, 2023 | Sep 7, 2023 |
| 10-Q | Quarterly report | Aug 16, 2023 | Jun 30, 2023 |
| NT 10-Q | Filing | Aug 14, 2023 | Jun 30, 2023 |
| 8-K |
Current report
Material agreement, Bylaw or fiscal year change
|
Jul 24, 2023 | Jul 24, 2023 |
| 424B4 | Prospectus | Jul 21, 2023 | — |
| CERT | Filing | Jul 20, 2023 | — |
| 8-K |
Current report
Change to shareholder rights, Bylaw or fiscal year change
|
Jul 20, 2023 | Jul 20, 2023 |
| EFFECT | Filing | Jul 19, 2023 | — |
| 8-A12B | Form 8-a12b | Jul 19, 2023 | — |
| S-1/A | Amended registration statement | Jul 17, 2023 | — |
| S-1/A | Amended registration statement | Jul 5, 2023 | — |
| DEF 14C | Information statement | May 17, 2023 | May 16, 2023 |
| 10-Q | Quarterly report | May 9, 2023 | Mar 31, 2023 |
| S-1/A | Amended registration statement | May 9, 2023 | — |
| 10-K | Annual report | Mar 31, 2023 | Dec 31, 2022 |
| DEFR14C | Filing | Mar 10, 2023 | — |
| DEF 14C | Information statement | Feb 21, 2023 | Feb 21, 2023 |
| S-1 | Registration statement | Feb 14, 2023 | — |
| PRE 14C | Filing | Feb 10, 2023 | Feb 10, 2023 |
| 10-Q | Quarterly report | Nov 14, 2022 | Sep 30, 2022 |
| 10-Q | Quarterly report | Aug 15, 2022 | Jun 30, 2022 |
| 8-K |
Current report
Officer or director change
|
Aug 15, 2022 | Aug 9, 2022 |
| 10-Q | Quarterly report | May 16, 2022 | Mar 31, 2022 |
| 10-K | Annual report | Apr 6, 2022 | Dec 31, 2021 |
| NT 10-K | Filing | Apr 1, 2022 | Dec 31, 2021 |
| 10-Q | Quarterly report | Nov 15, 2021 | Sep 30, 2021 |
| 10-Q | Quarterly report | Aug 12, 2021 | Jun 30, 2021 |
| 10-Q | Quarterly report | May 18, 2021 | Mar 31, 2021 |
| NT 10-Q | Filing | May 17, 2021 | Mar 31, 2021 |
| 10-K | Annual report | Mar 30, 2021 | Dec 31, 2020 |
| 8-K/A |
Amended current report
Material agreement, Acquisition or sale of assets
|
Mar 11, 2021 | Dec 31, 2020 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Change in control
|
Jan 7, 2021 | Dec 31, 2020 |
| 8-K |
Current report
Material agreement
|
Dec 30, 2020 | Dec 24, 2020 |
| 8-K |
Current report
Other events
|
Dec 22, 2020 | Dec 17, 2020 |
| 8-K |
Current report
Officer or director change
|
Dec 10, 2020 | Nov 27, 2020 |
| 10-Q/A | Amended quarterly report | Nov 9, 2020 | Sep 30, 2020 |
| 10-Q | Quarterly report | Nov 3, 2020 | Sep 30, 2020 |
| 8-K |
Current report
Auditor change
|
Oct 8, 2020 | Oct 1, 2020 |
| 10-Q | Quarterly report | Aug 11, 2020 | Jun 30, 2020 |
| 10-Q | Quarterly report | May 8, 2020 | Mar 31, 2020 |
| 10-K | Annual report | Mar 31, 2020 | Dec 31, 2019 |
| NT 10-K | Filing | Mar 30, 2020 | Dec 31, 2019 |
| 10-Q | Quarterly report | Nov 14, 2019 | Sep 30, 2019 |
| 8-K |
Current report
Material agreement
|
Oct 15, 2019 | Oct 1, 2019 |
| 10-Q | Quarterly report | Aug 9, 2019 | Jun 30, 2019 |
| 10-Q | Quarterly report | May 15, 2019 | Mar 31, 2019 |
| EFFECT | Filing | Apr 3, 2019 | — |
| CORRESP | Letter to the SEC | Apr 2, 2019 | — |
| CORRESP | Letter to the SEC | Apr 2, 2019 | — |
| S-1/A | Amended registration statement | Mar 27, 2019 | — |
| UPLOAD | Letter from the SEC | Mar 4, 2019 | — |
| S-1/A | Amended registration statement | Feb 25, 2019 | — |
| UPLOAD | Letter from the SEC | Feb 19, 2019 | — |
| S-1 | Registration statement | Jan 29, 2019 | — |
Showing 132 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Services-Medical Laboratories (SIC 8071)
- Listed as
- BGLC (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- WY
- Headquarters
- Kuala Lumpur
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1737523
- Former names
- BioNexus Gene Lab Coporation (until May 8, 2020)
Other Services-Medical Laboratories companies
- Natera, Inc. NTRA
- Labcorp Holdings Inc. LH
- Quest Diagnostics Inc DGX
- Guardant Health, Inc. GH
- Caris Life Sciences, Inc. CAI
- GRAIL, Inc. GRAL
- RadNet, Inc. RDNT
- BillionToOne, Inc. BLLN
Source: SEC EDGAR filings. This is company-reported data, not investment advice.